As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
COVID-19 and impact on peer review
Experimental Hematology & Oncology accepted for inclusion in SCIE
We are delighted to announce that Experimental Hematology & Oncology has been accepted for inclusion in Science Citation Index Expanded (SCIE), a key database of Web of Science, published by Clarivate Analytics. Starting 2020, Experimental Hematology & Oncology will be published in the annual Journal Citation Reports, at which point it will receive the associated journal metrics, such as Immediacy Index, Eigenfactor Score, and Journal Impact Factor.
Aims and scope
Experimental Hematology & Oncology is an open access journal that encompasses all aspects of hematology and oncology with an emphasis on preclinical, basic, patient-oriented and translational research. The journal acts as an international platform for sharing laboratory findings in these areas and makes a deliberate effort to publish clinical trials with 'negative' results and basic science studies with provocative findings.
Articles
-
-
Indirect comparison of azacitidine and decitabine for the therapy of elderly patients with acute myeloid leukemia: a systematic review and network meta-analysis
-
Gene mutational analysis by NGS and its clinical significance in patients with myelodysplastic syndrome and acute myeloid leukemia
-
The SMAC mimetic LCL-161 selectively targets JAK2V617F mutant cells
-
Immune pressures drive the promoter hypermethylation of neoantigen genes
The Article to this article has been published in Nature 2019 567:1032
-
Breast cancer brain metastases: the last frontier
-
CD19: a biomarker for B cell development, lymphoma diagnosis and therapy
-
Metaplastic breast cancer: histologic characteristics, prognostic factors and systemic treatment strategies
-
The development of bispecific antibodies and their applications in tumor immune escape
-
Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis
Editors-in-Chief
Kongming Wu, Tongji Medical College
Delong Liu, New York Medical College
Zihai Li, Medical University of South Carolina
Editor's quote (Dr. Delong Liu)
"Like our companion journal, Journal of Hematology & Oncology, Experimental Hematology & Oncology publishes on all aspects of hematology and oncology, which are closely intertwined and rapidly evolving fields. It also emphasizes basic and translational research, as well as patient-oriented research and clinical trials with ‘negative’ or preliminary results. The journal is an international platform for sharing findings in these areas and adheres to fast turnaround times."
Advertisement
Follow
Annual Journal Metrics
-
Speed
34 days to first decision for reviewed manuscripts only
27 days to first decision for all manuscripts
56 days from submission to acceptance
12 days from acceptance to publicationCitation Impact
0.875 - Source Normalized Impact per Paper (SNIP)
0.988 - SCImago Journal Rank (SJR)
2.810 - CitescoreUsage
174,663 Downloads
48 Altmetric Mentions
On the blog
-
Looking beyond physical health for World Cancer Day 2020
24 January 2020
-
Breast Cancer Quiz 2019
30 September 2019
-
Sharing data for the benefit of children with cancer
09 September 2019
Advertisement
